Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG

BACKGROUND: The question of how to set the cost-effectiveness threshold for new, innovative medicines is a matter of ongoing controversy. One prominent proposal suggests that the cost-effectiveness threshold adopted by the U.K. National Institute for Health and Care Excellence (NICE) should represen...

Descripción completa

Detalles Bibliográficos
Autor principal: Gandjour, Afschin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178559/
https://www.ncbi.nlm.nih.gov/pubmed/32321496
http://dx.doi.org/10.1186/s12913-020-5050-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178559/
https://www.ncbi.nlm.nih.gov/pubmed/32321496
http://dx.doi.org/10.1186/s12913-020-5050-9

Ejemplares similares